The global acute conjunctivitis treatment market size was valued at USD 4.8 billion in 2022 and is anticipated to grow at USD 6.5 billion by 2029 recording a CAGR of 4.0% from the forecast period 2023-2029.
Technological advancements in the sector and increased utilization in personalized medicines, cancer diagnostics, and treatment drive the growth of the global biochip market. However, high cost of R&D activities related to biochips hampers the market
North America accounted for nearly two-fifths of the total market share in 2017 and will maintain its leadership status by 2025. This is due to rise in funding by various organizations, implementation of agreements
